Emerging cardiac markers in coronary disease: Role of brain natriuretic peptide and other biomarkers

Minerva Cardioangiologica

Volumn 55, Issue 4, 2007, Pages 491-496

  Palazzuoli, A ^a,b   Iovine, F ^a   Gallotta, M ^a   Nuti, R ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Coronary artery disease; Coronary vessels; Natriuretic peptide, brain

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE MB; TROPONIN;

ACUTE CORONARY SYNDROME; CORONARY ARTERY DISEASE; HEART FAILURE; HUMAN; LABORATORY DIAGNOSIS; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; METALLOPROTEINS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TROPONIN;

EID: 35948971470     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Rutherford JD, Braunwald E. Coronary heart disease. In: Braunwald E editor. Heart Diseases. 5 ed. Philadelphia: Saunders; 1997. p. 1799-869.
2. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G et al. The TIMI risk score for unstable angina/ non ST elevation ML a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
3. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L; FRISC II (Fast Revascularization during Instability in CAD) Investigators. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979-86.
4. Ottervanger JP, Armostrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM et al. Long term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one year survival in the GUSTO IV-ACS Trial. Circulation 2003;107:437-42.
5. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
6. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F et al. Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 2001;103: 2236-49.
7. Caligiuri G, Liuzzo G, Biasucci LM, Maseri A. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol 1998;32:1295-304.
8. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
9. Toss H, Lindahl B, Siegbahn A, Wallentin L for the FRISC study group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96:4204-10.
10. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB et al. The prognostic value of C reactive protein and serum amyloid A protein in severe unstable angina. New Engl J Med 1994;331:417-24.
11. Haverkate F, Thompson FG, Pyke SDM, Gallimore JR, Pepys MB for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
12. De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease: cause or effect? J Am Coll Cardiol 2005;46:1496-502.
13. Galis Z, Khatri J. Metalloproteinases in vascular modeling and atherogenesis: the good, the bad and the ugly. Circ Res 2003;90:251-62.
14. Eckart R, Uyehara C, Shry E, Furgerson J, Krasuski R. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol 2004;17:27-31.
15. Soejima H, Ogawa H, Sakamoto T, Miyamoto S, Kajiwara I, Kojima S et al. Increased serum matrix metalloproteinase-1 concentration predicts advanced left ventricular remodeling in patients with acute myocardial infarction. Circ J 2003;67:301-4.
16. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
17. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T et al. Myeloperoxidase serum levels predict risk in patient with acute coronary syndromes. Circulation 2003;108:1440-5.
18. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxigenates the cysteine switch domain of MMP-7: a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-87.
19. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A et al. Myeloperoxydase, a leukocyte derived vascular NO oxidase. Science 2002;296:2391-4.
20. Bayes-Genis A, Schwartz R, Lewis D, Overgaard M, Christiansen M, Oxvig C et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001;21:335-41.
21. Lund J, Qin Q, Ilva T, Pettersson K, Voipio-Pulkki L, Porela P et al. Circulating pregnancy-associated plasma protein A preditcs outcome in patients with acute coronary syndrome but no troponine I elevation. Circulation 2003;104:1924-26.
22. Heeschen C, Dimmeler S, Hamm C, Fichtischerer S, Simoons M, Zeiher A. Pregnancy-associated plasma protein A levels in patients with acute coronary syndromes. J Am Coll Cardiol 2005;45:229-37.
23. Beaudeux JL, Burc L, Imbert-Bismut F, Giral P, Bernard M, Bruckert E et al. Serum plasma associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Artherioscler Thromb Vasc Biol 2003;23:e97-e101.
24. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
25. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004;44:1988-95.
26. Forte RS, Pearlman JD, Siegel AH, Yeo KT. Detection of exercise-induced myocardial ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 2004;44: 1980-7.
27. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
28. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
29. Morrow DA, de Lemos J, Sabatine M, Murphy SA, Demopoulos LA, Dibattiste PM et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non ST-elevation myocardial infarction. J Am Coll Cardiol 2003;41:1264-72.
30. Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PM, Morrow DA et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:564-8.
31. Palazzuoli A, Gennari L, Calabria P, Quatrini I, Vecchiato L, De Paola V et al. Relation of plasmabrain natriuretic peptide levels in non-ST coronary disease and preserved systolic function to number of narrowed coronary arteries. Am J Cardiol 2005;96:1705-10.
32. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Colch) 1995;88:551-6.
33. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N- terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000;84:421-4.
34. Sabatine MS, Morrow DA, De Lemos JA, Gibson CM, Murphy SA, Rifai N et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Circulation 2002;105:1760-3.
35. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from Heart and Soul study. Circulation 2003;108:2987-92.
36. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW et al. Plasma natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. A comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
37. Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentration predict survival after acute myocardial infarction. J Am Coll Cardiol 1996;27:1656-61.
38. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary sydromes. Eur J Heart Fail 2004;6:327-33.
39. Kikuta K, Yasue H, Yoshimura M, Caidahl K, Lie RT, Nilsen DW et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996;132:101-7.
40. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes moving toward multimarker strategy. Circulation 2003;108:250-2.